Olema Pharmaceuticals/$OLMA
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Olema Pharmaceuticals
Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline.
- Ticker
- $OLMA
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 150
- Headquarters
- San Francisco, United States
- Website
- olema.com
OLMA Metrics
BasicAdvanced
$641M
-
-$2.13
2.01
-
Price and volume
Market cap
$641M
Beta
2.01
52-week high
$36.26
52-week low
$6.24
Average daily volume
1.3M
Financial strength
Current ratio
8.863
Quick ratio
8.757
Long term debt to equity
0.007
Total debt to equity
0.009
Profitability
EBITDA (TTM)
-220.675
Management effectiveness
Return on assets (TTM)
-31.82%
Return on equity (TTM)
-52.74%
Valuation
Price to book
1.49
Price to tangible book (TTM)
1.49
Price to free cash flow (TTM)
-4.27
Free cash flow yield (TTM)
-23.42%
Free cash flow per share (TTM)
-1.717
Growth
Earnings per share change (TTM)
9.98%
3-year earnings per share growth (CAGR)
-4.11%
What the Analysts think about OLMA
Analyst ratings (Buy, Hold, Sell) for Olema Pharmaceuticals stock.
Analyst projections of the future price of Olema Pharmaceuticals stock.
Bulls say / Bears say
Management cited Phase 2 median progression-free survival of 7 months in ESR1-mutant patients and 5.5 months in wild-type patients, suggesting palazestrant may have activity across both groups being tested in Phase 3. OPERA-01 is fully enrolled, with results expected in the first quarter of 2027. (Investing.com, Olema Pharmaceuticals)
Initial Phase 1 results for OP-3136 showed no dose-limiting toxicities at tested doses and two confirmed partial responses among 19 patients whose tumours could be assessed. The early signal gives Olema a second potential drug programme beyond palazestrant. (Olema Pharmaceuticals)
Olema reported $461.1 million in cash, equivalents and marketable securities at the end of June 2026. Management said available resources should fund its current operating plan for at least 12 months, giving it scope to advance its clinical programmes without immediate financing pressure. (U.S. Securities and Exchange Commission)
OPERA-01's top-line readout moved from the expected fall of 2026 to the first quarter of 2027, pushing back a major catalyst and prolonging uncertainty over palazestrant's pivotal trial. (Olema Pharmaceuticals, Olema Pharmaceuticals)
AstraZeneca's Phase 3 SERENA-4 trial failed to meet its primary endpoint in first-line ER-positive, HER2-negative breast cancer. That result raises questions about the oral SERD class and could weigh on expectations for Olema's own first-line OPERA-02 study. (Investing.com)
Olema's second-quarter net loss widened to $63.2 million from $43.8 million a year earlier, as research and development and corporate costs rose. Continued spending on late-stage trials and commercial preparations could put further pressure on its cash balance. (Olema Pharmaceuticals)
Data summarised monthly by Lightyear AI. Last updated on 20 Oct 2026.
OLMA Financial Performance
Revenues and expenses
OLMA Earnings Performance
Company profitability
Upcoming events
No upcoming events
OLMA News
AllArticlesVideos
Funds containing OLMA
Fund name | Fund size | $OLMA weighting |
|---|---|---|
iShares Nasdaq US Biotechnology$BTEC | $1.1B | 0.04% |
iShares Nasdaq US Biotechnology£BTEK | $1.1B | 0.04% |
SPDR Russell 2000 US Small Cap€R2US | $5.3B | 0.02% |
SPDR Russell 2000 US Small Cap£R2SC | $5.3B | 0.02% |
Xtrackers MSCI World Small Cap$XSWC | $183M | 0.00% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.